JointHealth™ express   August 10, 2019

Correction to JointHealth™ express

Correction to the JointHealth™ express of August 9, 2019 listing for baricitinib (Olumiant®) and etanercept (Erelzi®) in Quebec

Our August 9, 2019 JointHealth™ express incorrectly reported that baricitinib (Olumiant®) for the treatment of rheumatoid arthritis (RA) and etanercept (Erelzi®) for the treatment of psoriatic arthritis (PsA) were listed on the Quebec drug formulary (la RAMQ). While they have received a positive recommendation to list from the Institut national d'excellence en santé et services sociaux (INESSS), they are not yet listed on the province’s formulary.